Optum: Why payers should be watching flurry of drug development activity around eczema
FierceHealthIT
MAY 3, 2021
Optum: Why payers should be watching flurry of drug development activity around eczema. Mon, 05/03/2021 - 15:53.
FierceHealthIT
MAY 3, 2021
Optum: Why payers should be watching flurry of drug development activity around eczema. Mon, 05/03/2021 - 15:53.
Digital Health Global
NOVEMBER 12, 2024
The company’s decline Since its peak valuation of $6 billion in 2021, 23andMe’s share price has plunged by 99%. 23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. As the consumer DNA testing market has matured, growth has slowed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healthcare IT Today
MARCH 3, 2025
The CRO industry has remained stagnant with extremely limited adoption of technology or modern approaches to streamline clinical development. From 2021 to 2022 alone, the cost of developing a single drug was estimated to have increased by almost $300M.
Healthcare IT Today
NOVEMBER 6, 2023
” The acquisition follows AllStripes’ $50 million Series B funding round in 2021 and PicnicHealth’s $60 million Series C round in 2022. . “PicnicHealth will continue both companies’ work to harness the power of patient data to support biomedical research.” Originally announced October 23rd, 2023
Digital Health Global
JANUARY 25, 2024
Biomarkers will help select patients whose cancer biologies are best suited to treatment with the right drug targeting the active disease mechanism. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.
ActiGraph
FEBRUARY 1, 2023
Drug development success rates have been on the decline since 2015. Compounded by the pandemic, trial success rates fell to a 10-year low in 2021, averaging only a 5% likelihood of successful progression through all phases. 1 The machinery of clinical development urgently needs some new oil.
ActiGraph
FEBRUARY 1, 2023
Drug development success rates have been on the decline since 2015. Compounded by the pandemic, trial success rates fell to a 10-year low in 2021, averaging only a 5% likelihood of successful progression through all phases. 1 The machinery of clinical development urgently needs some new oil.
Let's personalize your content